| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048859699 |
| P356 | DOI | 10.2165/11599310-000000000-00000 |
| P8608 | Fatcat ID | release_z5yslga2y5bazmfly34mnstsby |
| P698 | PubMed publication ID | 22356288 |
| P2093 | author name string | Douglas G Johns | |
| Brian K Hubbard | |||
| Michael J Forrest | |||
| Timothy Fisher | |||
| Joseph Duffy | |||
| P2860 | cites work | Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc | Q46231225 |
| Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia | Q46370170 | ||
| Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects | Q46518415 | ||
| Polymorphisms associated with cholesterol and risk of cardiovascular events | Q46691746 | ||
| JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways | Q46700745 | ||
| Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies | Q46858990 | ||
| Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. | Q53569234 | ||
| Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation | Q55670472 | ||
| Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death | Q64996196 | ||
| High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study | Q68689669 | ||
| Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits | Q74230827 | ||
| Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis | Q74290884 | ||
| Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport | Q80819953 | ||
| A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly | Q23913851 | ||
| HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway | Q24323992 | ||
| Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins | Q24336646 | ||
| Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels | Q24562095 | ||
| Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure | Q24624286 | ||
| Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial | Q24648125 | ||
| Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study | Q24649155 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis | Q28209813 | ||
| Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study | Q28216693 | ||
| Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial | Q28236480 | ||
| Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib | Q28240147 | ||
| Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol | Q28255410 | ||
| Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels | Q28272269 | ||
| Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin | Q28272279 | ||
| Effect of torcetrapib on the progression of coronary atherosclerosis | Q28295023 | ||
| Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia | Q28295044 | ||
| Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients | Q28308033 | ||
| Effects of torcetrapib in patients at high risk for coronary events | Q29619609 | ||
| Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer pro | Q33390281 | ||
| Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats | Q33569541 | ||
| Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms | Q33612543 | ||
| Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community | Q33639433 | ||
| Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial | Q34120778 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines | Q34347054 | ||
| High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies | Q34496492 | ||
| Safety and tolerability of dalcetrapib | Q34658775 | ||
| Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease | Q35086131 | ||
| Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters | Q35380101 | ||
| CETP gene variation: relation to lipid parameters and cardiovascular risk | Q35830944 | ||
| Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches | Q35860029 | ||
| A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study | Q36016822 | ||
| Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease | Q36386686 | ||
| Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone | Q36736504 | ||
| Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk | Q37193386 | ||
| High-density lipoproteins, inflammation and oxidative stress | Q37348323 | ||
| Aldosterone, sodium, and hypertension: lessons from torcetrapib? | Q37667391 | ||
| Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. | Q38481069 | ||
| High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. | Q39402383 | ||
| The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study | Q39433797 | ||
| Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels | Q39700827 | ||
| MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages | Q39751928 | ||
| Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition | Q39891782 | ||
| Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway | Q39911385 | ||
| Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials | Q40025523 | ||
| High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study | Q40070458 | ||
| Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits | Q40166036 | ||
| Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein | Q40768324 | ||
| A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits | Q40866383 | ||
| Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: effects of torcetrapib | Q42077639 | ||
| Biochemical characterization of cholesteryl ester transfer protein inhibitors | Q42107210 | ||
| Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport | Q42126715 | ||
| Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib | Q42562376 | ||
| Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease | Q42807626 | ||
| Design of a novel class of biphenyl CETP inhibitors | Q42839823 | ||
| Novel tetrahydrochinoline derived CETP inhibitors | Q43170785 | ||
| Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition | Q43201715 | ||
| Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. | Q43230598 | ||
| Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs | Q43273355 | ||
| Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage | Q43955475 | ||
| Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein | Q44441539 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. | Q45934900 | ||
| Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. | Q45958080 | ||
| Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. | Q46004811 | ||
| The off-target effects of torcetrapib | Q46041867 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| protein structure | Q735188 | ||
| P304 | page(s) | 491-507 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors | |
| P478 | volume | 72 |
| Q26746054 | Adipocytes, aldosterone and obesity-related hypertension |
| Q34858025 | Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin |
| Q47399773 | Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. |
| Q38051303 | Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib |
| Q38147723 | Clinical relevance of target identity and biology: implications for drug discovery and development |
| Q47431168 | Design, Synthesis, and Biological Evaluation of N,N-Disubstituted-4-Arylthiazole-2-Methylamine Derivatives as Cholesteryl Ester Transfer Inhibitors. |
| Q38966078 | Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a Structure-Guided Approach |
| Q34823459 | Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q30275688 | Genetic variants in CETP increase risk of intracerebral hemorrhage |
| Q38418951 | Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility |
| Q91937522 | Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case |
| Q26823249 | Novel therapies focused on the high-density lipoprotein particle |
| Q33402921 | Tangier disease: epidemiology, pathophysiology, and management |
| Q90607335 | The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range |
| Q26859507 | The role of advanced lipid testing in the prediction of cardiovascular disease |
Search more.